Suggested Reads

Your blog category

Scope Technologies Introduces BlueprintScope for New Home Builders

Scope today unveiled an all-new BlueprintScope report, designed for new home builders that design and build home models with multiple configurations and floor plan options. This new product is the first of its kind, allowing new construction specialty contractors and the building material distributors the ability to eliminate mistakes when bidding new construction opportunities. BlueprintScope […]

Scope Technologies Introduces BlueprintScope for New Home Builders Read More »

FDA Grants VERO Biotech Expanded Access Emergency Use for the Treatment of Patients with COVID-19, with the GENOSYL® DS, the First and Only FDA-Approved Tankless System for the Delivery of Inhaled Nitric Oxide

The recently FDA-approved GENOSYL® inhaled nitric oxide may have pulmonary and antiviral benefits in treating pulmonary hypertension and acute infectious diseases associated with the novel coronavirus[1] GENOSYL® DS facilitates outpatient use of inhaled nitric oxide in the treatment of cardiopulmonary symptoms associated with COVID-19 • GENOSYL is contraindicated in the treatment of neonates dependent on

FDA Grants VERO Biotech Expanded Access Emergency Use for the Treatment of Patients with COVID-19, with the GENOSYL® DS, the First and Only FDA-Approved Tankless System for the Delivery of Inhaled Nitric Oxide Read More »

Tolero Pharmaceuticals Joins The Leukemia & Lymphoma Society\\\’s Groundbreaking Beat AML Master Clinical Trial for Patients with Acute Myeloid Leukemia

Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncological diseases, today announced that it has joined The Leukemia & Lymphoma Society (LLS) in the groundbreaking, collaborative Beat AML Master Clinical Trial for newly diagnosed patients 60 years of age or older with acute myeloid leukemia (AML). Tolero\\\’s investigational agent,

Tolero Pharmaceuticals Joins The Leukemia & Lymphoma Society\\\’s Groundbreaking Beat AML Master Clinical Trial for Patients with Acute Myeloid Leukemia Read More »

Nu-X Ventures to deliver free hand sanitizer to Los Angeles citizens and hospitals

Los Angeles Based Nu-X Ventures, will begin delivering free hand sanitizer to the citizens of Los Angeles starting on 03/27/20. In what they are currently calling Project Blue Horizon, Nu-X Ventures is planning to leverage it\\\’s manufacturing resources to produce, deliver and supply bottles of free hand sanitizer over the next few weeks to people

Nu-X Ventures to deliver free hand sanitizer to Los Angeles citizens and hospitals Read More »

Alamo Group Inc. Highlights Operational Status

Alamo Group Inc. (NYSE: ALG) today announced that several of its manufacturing operations are either temporarily closed or reducing their level of production due to repercussions from the COVID-19 pandemic. Most of the Company\\\’s products have been deemed essential in the various jurisdictions where the Company operates, so while many of the Company\\\’s facilities continue

Alamo Group Inc. Highlights Operational Status Read More »

MyTelemedicine Rolls Out Rapid Response Virtual Care Platform for Independent Providers, Practices, Hospitals to Perform Video Visits

MyTelemedicine announced the release of its Rapid Response Virtual Care Platform. This rollout brings expanded capabilities to their already robust telehealth platform, giving doctors, group practices, and hospital systems the ability to consult virtually with their patients. MyTelemedicine\\\’s virtual care platform can assist healthcare providers better meet increased demand to manage and treat patients while

MyTelemedicine Rolls Out Rapid Response Virtual Care Platform for Independent Providers, Practices, Hospitals to Perform Video Visits Read More »

Evox Therapeutics and Takeda Sign Multi-target Rare Disease Collaboration

Collaboration focuses on developing novel protein replacement and mRNA therapies and explores the targeted delivery of these payloads using Evox\\\’s proprietary exosome technology Partnership encompasses up to five rare disease targets, including Evox\\\’s Niemann-Pick Type C programme, with Takeda assuming responsibility for its clinical development Evox Therapeutics Ltd (\\\’Evox\\\’ or the \\\’Company\\\’), a leading exosome

Evox Therapeutics and Takeda Sign Multi-target Rare Disease Collaboration Read More »

Stellar Solar Launches Restaurant Referral Program

Stellar Solar, one of San Diego\\\’s most experienced residential and commercial installers since 1998, has launched a unique program designed to help San Diego County restaurants generate extra revenue while generating solar leads and sales, creating a mutually beneficial scenario during these difficult times. The program pays participating restaurants $200 per lead and $750 per

Stellar Solar Launches Restaurant Referral Program Read More »

VPNoverview.com: Simply Changing Settings on Booking Sites Might Get You Home Far Quicker and Cheaper in Times of Crisis

Air traffic is coming to a standstill due to the advance of the corona virus. As a result, countless people from all over the world are stuck in a foreign country, looking for a way home. VPNoverview\\\’s research team examined several flight options that are still available via large booking sites. For anyone who is

VPNoverview.com: Simply Changing Settings on Booking Sites Might Get You Home Far Quicker and Cheaper in Times of Crisis Read More »

Global Private LTE Market Study, 2018-2020 & Beyond – Featuring Profiles of Cisco, Ericsson, Huawei, Samsung, Verizon, and More

The \\\”Private LTE Market to 2027 – Global Analysis and Forecasts by Component; Type; End-user\\\” report has been added to ResearchAndMarkets.com\\\’s offering. The global private LTE market accounted for US$ 2,631.9 million in 2018 and is expected to grow at a CAGR of 12.7% over the forecast period 2019-2027, to account for US$ 7,533.4 million

Global Private LTE Market Study, 2018-2020 & Beyond – Featuring Profiles of Cisco, Ericsson, Huawei, Samsung, Verizon, and More Read More »

Scroll to Top